← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 2001First marketed drug
Jun 25, 2018First NDA
Jun 25, 2018Last known activity
Jul 31, 2021
Acquired by Jazz Pharmaceuticals on Feb 3, 2021
Timeline
1990s
- Jul 1, 1998
GW Pharmaceuticals Ltd.— Founded
2010s
- Jun 25, 2018
cannabidiol— NDA Organization
2020s
- Feb 3, 2021
Jazz Pharmaceuticals— Acquired By
Drugs by trial phase (11 distinct, 47 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Approved for
Studied for
- Blepharospasm
- Brain Stem Infarctions
- Cancer Pain
- Diabetic Neuropathies
- Huntington Disease
- Hyperalgesia
- Kidney Diseases
- Kidney Failure, Chronic
- Klippel-Trenaunay-Weber Syndrome
- Marijuana Abuse
- Mucositis
- Multiple Sclerosis
- Muscle Spasticity
- Nausea
- Neoplasms
- Neuralgia
- Peripheral Nervous System Diseases
- Postoperative Nausea and Vomiting
- Postoperative Pain
- Renal Insufficiency
- Sclerosis
- Spinal Cord Injuries
- Squamous Cell Carcinoma of Head and Neck
- Stress Disorders, Post-Traumatic
- Stress Disorders, Traumatic
- Sturge-Weber Syndrome
- Syndrome
- Vomiting
Marketed drugs (1)
Recent trials (48)
- NCT04984278Lead sponsorPhase 3Jul 31, 2021
- NCT04592159Lead sponsorPhase 2/Phase 3Feb 1, 2021
- NCT04657666Lead sponsorPhase 3Dec 31, 2020
- NCT04423341CollaboratorPhase 2/Phase 3May 20, 2020
- NCT04203498Lead sponsorPhase 3Mar 31, 2020
- NCT04447846CollaboratorPhase 2Oct 14, 2019
- NCT02660255CollaboratorN/AFeb 1, 2016
- NCT02325024Lead sponsorPhase 1Jan 1, 2016
- NCT02432612Lead sponsorPhase 1Oct 1, 2015
- NCT02283281CollaboratorPhase 2/Phase 3May 1, 2015
- NCT02332655CollaboratorPhase 1/Phase 2Dec 1, 2014
- NCT02325011Lead sponsorPhase 1Nov 1, 2014
- NCT02240160Lead sponsorPhase 1Aug 1, 2014
- NCT01975688Lead sponsorPhase 1Feb 1, 2014
- NCT01887301Lead sponsorPhase 1Jul 1, 2013
Details
- Founded
- Cambridge, GB Jul 1, 1998
- First NDA
- Jun 25, 2018
- Last known activity
- Jul 31, 2021
Designations held
- Orphan drug
- Fast track
- Priority review